Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Neurodegenerative DiseaseOrphan Drug

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739181

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739181

Metachromatic Leukodystrophy Treatment

PUBLISHED:
PAGES: 283 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Metachromatic Leukodystrophy Treatment Market to Reach US$3.3 Billion by 2030

The global market for Metachromatic Leukodystrophy Treatment estimated at US$2.6 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Atidarsagene Autotemcel Drug Type, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the DUOC-01 Drug Type segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$697.9 Million While China is Forecast to Grow at 8.2% CAGR

The Metachromatic Leukodystrophy Treatment market in the U.S. is estimated at US$697.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$691.8 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Metachromatic Leukodystrophy Treatment Market - Key Trends & Drivers Summarized

Why Does Metachromatic Leukodystrophy Demand Urgent and Specialized Therapeutic Strategies?

Metachromatic leukodystrophy (MLD) is a rare, inherited lysosomal storage disorder that results in the progressive destruction of myelin-the protective sheath surrounding nerve cells in the brain and peripheral nervous system. Caused by a deficiency in the enzyme arylsulfatase A (ARSA), MLD leads to the accumulation of sulfatides, which are toxic to oligodendrocytes and Schwann cells. The condition is severe, often fatal, and manifests in late-infantile, juvenile, or adult forms, each with varying symptom onset and progression speed.

Symptoms typically include motor regression, spasticity, cognitive decline, seizures, and loss of speech and mobility, rendering patients completely dependent within a few years of diagnosis. The absence of curative options for many years made symptom management the mainstay of care. However, breakthroughs in gene therapy, enzyme replacement, and hematopoietic stem cell transplantation (HSCT) are now redefining therapeutic potential. With early diagnosis being critical to effectiveness, the market is increasingly centered around newborn screening, early intervention, and high-precision genetic targeting.

How Are Gene Therapies and Enzyme-Based Approaches Changing the Treatment Paradigm?

The emergence of gene therapy has marked a turning point in MLD treatment. The most notable innovation is Libmeldy (atidarsagene autotemcel), the first approved ex vivo gene therapy for MLD, developed by Orchard Therapeutics. This therapy involves extracting the patient's hematopoietic stem cells, inserting a functional copy of the ARSA gene using a lentiviral vector, and re-infusing the modified cells after myeloablative conditioning. Administered early-before symptom onset-this approach has shown significant promise in halting or slowing disease progression, particularly in pre-symptomatic patients.

Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are also being investigated. Recombinant ARSA enzymes delivered intravenously or intrathecally are being tested to overcome the blood-brain barrier and replenish deficient activity. Adjunct strategies, such as small molecules to reduce sulfatide accumulation or chaperone therapies to stabilize mutant enzymes, are gaining traction in preclinical studies. The field is rapidly advancing through collaboration between biopharma firms, rare disease foundations, and regulatory agencies prioritizing orphan drug development and accelerated approval pathways.

Which Patient Populations, Research Institutions, and Regions Are Driving Therapeutic Development?

The primary patient population comprises children diagnosed with late-infantile and juvenile forms of MLD-who represent the largest share of clinical interventions due to earlier onset and faster decline. These patients are typically diagnosed through family history, neurological assessments, or expanded newborn screening panels in countries with rare disease surveillance programs. Adult-onset MLD patients, while rarer and slower progressing, are increasingly participating in natural history studies and registries to better understand therapeutic windows and biomarker development.

Europe remains the leading region for MLD therapeutic development, with the U.K., Germany, and Italy hosting several clinical centers, research collaborations, and regulatory pilots. North America is rapidly expanding its clinical research footprint, with U.S. institutions like the NIH, Mayo Clinic, and CHOP contributing to trials and long-term outcome data. Asia-Pacific is in earlier stages of diagnostic infrastructure development but is seeing growing interest in rare disease funding, gene therapy localization, and neonatal genomics initiatives, particularly in Japan, South Korea, and China.

What Is Driving Long-Term Growth in the MLD Treatment Market and What Challenges Remain?

The growth in the MLD treatment market is driven by precision medicine breakthroughs, orphan drug incentives, and increased diagnostic awareness. Accelerated approval mechanisms, pediatric rare disease vouchers, and growing rare disease advocacy are creating a favorable policy environment for high-risk, high-cost therapies. As more countries implement genetic screening at birth, the ability to identify pre-symptomatic MLD cases will expand the eligible population for early therapeutic intervention-particularly for gene therapy candidates with time-sensitive efficacy.

Despite these advances, challenges remain. High therapy costs, manufacturing complexity, and limited treatment centers hinder global access. Ensuring long-term efficacy, safety surveillance, and equitable reimbursement mechanisms for one-time gene therapies are pressing concerns. Additionally, adult and advanced-stage patients have limited options, necessitating continued research into neuroregenerative strategies and CNS-directed enzyme delivery.

As genetic therapies mature and personalized intervention protocols are refined, the MLD treatment landscape is poised for significant transformation-offering hope for what was once considered an untreatable and devastating neurodegenerative disorder.

SCOPE OF STUDY:

The report analyzes the Metachromatic Leukodystrophy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type, Other Drug Types); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Abeona Therapeutics Inc.
  • AGTC (Applied Genetic Technologies)
  • Amicus Therapeutics
  • ArmaGen Inc.
  • Asklepios BioPharmaceutical
  • Avrobio Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio, Inc.
  • BridgeBio Pharma
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Genethon
  • GlaxoSmithKline plc (GSK)
  • Homology Medicines, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Krystal Biotech, Inc.
  • Lysogene
  • Magenta Therapeutics
  • Orchard Therapeutics plc
  • Passage Bio, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34072

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Metachromatic Leukodystrophy Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Rare Disease Therapeutics Throws the Spotlight on Metachromatic Leukodystrophy Treatment
    • Advancements in Gene Therapy Platforms Drive Development of Curative MLD Interventions
    • Increased R&D Funding for Lysosomal Storage Disorders Spurs Clinical Pipeline Expansion
    • Global Regulatory Incentives and Orphan Drug Designations Strengthen Market Entry Opportunities
    • Expansion of Newborn Screening Programs Accelerates Early Diagnosis and Timely Treatment
    • Breakthroughs in Hematopoietic Stem Cell Transplantation Propel Treatment Efficacy in Pediatric Patients
    • Use of Viral Vectors and Genome Editing Tools Fuels Innovation in Ex Vivo Gene Therapies
    • Increased Collaboration Between Biopharma and Academia Supports Preclinical Study Advancements
    • Surge in Compassionate Use and Expanded Access Programs Accelerates Early Drug Adoption
    • Growing Demand for Multidisciplinary Care Models Strengthens Holistic Treatment Approaches
    • Government Grants and Rare Disease Policy Reforms Create Favorable Development Ecosystems
    • Improved Genetic Testing Technologies Enhance Patient Identification and Trial Enrollment
    • Emergence of Cell-Based and Regenerative Therapies Expands Therapeutic Modalities
    • Clinical Validation of Novel Delivery Systems for CNS-Targeted Therapies Boosts Market Confidence
    • Rising Advocacy by Rare Disease Foundations Spurs Patient Engagement and Clinical Trial Awareness
    • Growth in Pediatric Neurology Infrastructure Enhances Access to Specialized MLD Treatments
    • Limited Competition and High Unmet Need Strengthen Business Case for Innovative Drug Development
    • Rise in Biologics and Protein Replacement Research Generates Opportunities for Novel Modalities
    • Complex Manufacturing and Cost Challenges Drive Demand for Scalable Production Platforms
    • Long-Term Disease Progression Data From Ongoing Trials Supports Market Entry of Gene-Edited Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Metachromatic Leukodystrophy Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Atidarsagene Autotemcel Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Atidarsagene Autotemcel Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Atidarsagene Autotemcel Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for DUOC-01 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for DUOC-01 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for DUOC-01 Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for OTL-200 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for OTL-200 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for OTL-200 Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!